JP2015519396A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519396A5
JP2015519396A5 JP2015517311A JP2015517311A JP2015519396A5 JP 2015519396 A5 JP2015519396 A5 JP 2015519396A5 JP 2015517311 A JP2015517311 A JP 2015517311A JP 2015517311 A JP2015517311 A JP 2015517311A JP 2015519396 A5 JP2015519396 A5 JP 2015519396A5
Authority
JP
Japan
Prior art keywords
cancer
compound
salt
inden
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015517311A
Other languages
English (en)
Japanese (ja)
Other versions
JP6092376B2 (ja
JP2015519396A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044211 external-priority patent/WO2013188184A1/en
Publication of JP2015519396A publication Critical patent/JP2015519396A/ja
Publication of JP2015519396A5 publication Critical patent/JP2015519396A5/ja
Application granted granted Critical
Publication of JP6092376B2 publication Critical patent/JP6092376B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015517311A 2012-06-14 2013-06-05 Jak1およびjak2の阻害剤 Expired - Fee Related JP6092376B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659679P 2012-06-14 2012-06-14
US61/659,679 2012-06-14
PCT/US2013/044211 WO2013188184A1 (en) 2012-06-14 2013-06-05 Inhibitor of jak1 and jak2

Publications (3)

Publication Number Publication Date
JP2015519396A JP2015519396A (ja) 2015-07-09
JP2015519396A5 true JP2015519396A5 (enExample) 2016-06-30
JP6092376B2 JP6092376B2 (ja) 2017-03-08

Family

ID=48626679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517311A Expired - Fee Related JP6092376B2 (ja) 2012-06-14 2013-06-05 Jak1およびjak2の阻害剤

Country Status (14)

Country Link
US (1) US9062050B2 (enExample)
EP (1) EP2861231B1 (enExample)
JP (1) JP6092376B2 (enExample)
KR (1) KR20150008907A (enExample)
CN (1) CN104349775B (enExample)
AU (1) AU2013274641B2 (enExample)
BR (1) BR112014030651A2 (enExample)
CA (1) CA2871659C (enExample)
EA (1) EA201492104A1 (enExample)
ES (1) ES2605827T3 (enExample)
IN (1) IN2014MN02228A (enExample)
MX (1) MX2014015271A (enExample)
WO (1) WO2013188184A1 (enExample)
ZA (1) ZA201407940B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022184130A1 (zh) * 2021-03-03 2022-09-09 成都先导药物开发股份有限公司 一种nuak抑制剂及其用途
WO2023086320A1 (en) * 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CN116585312A (zh) * 2023-04-30 2023-08-15 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
WO2008129255A1 (en) 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2015519396A5 (enExample)
IL288341A (en) Targeted ligands for medicinal compounds, methods for their preparation and uses thereof
JP2014502638A5 (enExample)
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
JP2017505782A5 (enExample)
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
JP2016501221A5 (enExample)
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
JP2016533366A5 (enExample)
NZ706836A (en) Methods of treating cancer
JP2017514855A5 (enExample)
EA032972B1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
JP2017519027A5 (enExample)
RU2016146119A (ru) Новый кристалл тетрациклического соединения
EP3666273A3 (en) Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
JP2014508784A5 (enExample)
JP2015506352A5 (enExample)
IL238722B (en) New annals of indole for the treatment of cancer, viral infections, and lung disease
CN109563051A (zh) 作为pde4抑制剂的并环类化合物
RU2015149771A (ru) Противоопухолевое средство
JP2013540778A5 (enExample)
HK1198690A1 (en) Therapeutic use of imidazopyridine derivatives
JP2019521155A5 (enExample)